AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism[S]

ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel investigational drug being developed for the treatment of dyslipidemia and other cardio-metabolic risk factors. The hypolipidemic, anti-atherosclerotic, anti-obesity, and glucose-lowering properties of ETC-1002, characterized in preclinical disease models, are believed to be due to dual inhibition of sterol and fatty acid synthesis and enhanced mitochondrial long-chain fatty acid β-oxidation. However, the molecular mechanism(s) mediating these activities remained undefined. Studies described here show that ETC-1002 free acid activates AMP-activated protein kinase in a Ca2+/calmodulin-dependent kinase β-independent and liver kinase β 1-dependent manner, without detectable changes in adenylate energy charge. Furthermore, ETC-1002 is shown to rapidly form a CoA thioester in liver, which directly inhibits ATP-citrate lyase. These distinct molecular mechanisms are complementary in their beneficial effects on lipid and carbohydrate metabolism in vitro and in vivo. Consistent with these mechanisms, ETC-1002 treatment reduced circulating proatherogenic lipoproteins, hepatic lipids, and body weight in a hamster model of hyperlipidemia, and it reduced body weight and improved glycemic control in a mouse model of diet-induced obesity. ETC-1002 offers promise as a novel therapeutic approach to improve multiple risk factors associated with metabolic syndrome and benefit patients with cardiovascular disease.

[1]  J. Lowenstein,et al.  Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase. , 1969, Archives of biochemistry and biophysics.

[2]  J. Kastelein.  The future of lipid-lowering therapy: the big picture. , 2003, The Netherlands journal of medicine.

[3]  J. Bar-Tana,et al.  Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by beta, beta'-tetramethylhexadecanedioic acid (MEDICA 16). , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[4]  J. Ontko,et al.  Hypolipidemic activity of (−)-hydroxycitrate , 2006, Lipids.

[5]  A. Lombardi,et al.  Sequential changes in the signal transduction responses of skeletal muscle following food deprivation , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  L. Guarente.  The logic linking protein acetylation and metabolism. , 2011, Cell Metabolism.

[7]  J. Auwerx,et al.  Reversible acetylation of PGC-1: connecting energy sensors and effectors to guarantee metabolic flexibility , 2010, Oncogene.

[8]  M. Montminy,et al.  The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism , 2005, Nature.

[9]  B. Kalderon,et al.  Tissue selective modulation of redox and phosphate potentials by beta,beta'-methyl-substituted hexadecanedioic acid. , 1992, Endocrinology.

[10]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[11]  R. Endele,et al.  Species differences in induction of hepatic enzymes by BM 17.0744, an activator of peroxisome proliferator-activated receptor alpha (PPARα) , 1999, Archives of Toxicology.

[12]  David Carling,et al.  A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis , 1987, FEBS letters.

[13]  S. Cheema-Dhadli,et al.  Inhibition of enzymes which interact with citrate by (--)hydroxycitrate and 1,2,3,-tricarboxybenzene. , 1973, European journal of biochemistry.

[14]  A. Barthel,et al.  Regulation of the forkhead transcription factor FKHR (FOXO1a) by glucose starvation and AICAR, an activator of AMP-activated protein kinase. , 2002, Endocrinology.

[15]  J. Molero,et al.  Methazolamide Is a New Hepatic Insulin Sensitizer That Lowers Blood Glucose In Vivo , 2012, Diabetes.

[16]  J. G. Hamilton,et al.  Inhibition of lipogenesis in rat liver by (-)-hydroxycitrate. , 1972, Archives of biochemistry and biophysics.

[17]  R. Childress,et al.  Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia. , 2011, Journal of clinical lipidology.

[18]  Matthew K Ito,et al.  Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. , 2012, Journal of clinical lipidology.

[19]  A. Adler,et al.  Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance , 2009, BMJ : British Medical Journal.

[20]  M. Rigoulet,et al.  Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.

[21]  J. Olefsky,et al.  Insulin sensitivity: modulation by nutrients and inflammation. , 2008, The Journal of clinical investigation.

[22]  C. Ahn,et al.  Novel black soy peptides with antiobesity effects: activation of leptin-like signaling and AMP-activated protein kinase , 2008, International Journal of Obesity.

[23]  A. Pelletier,et al.  Ketone bodies alter dinitrophenol-induced glucose uptake through AMPK inhibition and oxidative stress generation in adult cardiomyocytes. , 2007, American journal of physiology. Endocrinology and metabolism.

[24]  T. Kadowaki,et al.  Acetic acid activates hepatic AMPK and reduces hyperglycemia in diabetic KK-A(y) mice. , 2006, Biochemical and biophysical research communications.

[25]  D. Tew,et al.  The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. , 1998, The Biochemical journal.

[26]  J. Krieglstein,et al.  Protein phosphatases types2Ca and 2C in apoptosis , 2006 .

[27]  N. Ruderman,et al.  Dietary polyunsaturated fatty acids enhance hepatic AMP-activated protein kinase activity in rats. , 2005, Biochemical and biophysical research communications.

[28]  B. Viollet,et al.  Hepatocyte Nuclear Factor-4α Involved in Type 1 Maturity-Onset Diabetes of the Young Is a Novel Target of AMP-Activated Protein Kinase , 2001 .

[29]  Y. Chao,et al.  High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. , 2001, European journal of pharmacology.

[30]  L. Madsen,et al.  Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. , 1999, Journal of lipid research.

[31]  Rick B. Vega,et al.  The Coactivator PGC-1 Cooperates with Peroxisome Proliferator-Activated Receptor α in Transcriptional Control of Nuclear Genes Encoding Mitochondrial Fatty Acid Oxidation Enzymes , 2000, Molecular and Cellular Biology.

[32]  R. Srivastava.  Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters. , 2011, Atherosclerosis.

[33]  J. Goldstein,et al.  Selective versus total insulin resistance: a pathogenic paradox. , 2008, Cell metabolism.

[34]  O. Pedersen,et al.  Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. , 2002, Diabetes.

[35]  I. Hamilton-Craig,et al.  Statin‐associated myopathy , 2001, The Medical journal of Australia.

[36]  Andrew A. Young,et al.  Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice , 2010, PloS one.

[37]  G. Vladutiu.  Genetic predisposition to statin myopathy , 2008, Current Opinion in Rheumatology.

[38]  W. Jung,et al.  Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice. , 2012, European journal of pharmacology.

[39]  P. Puigserver,et al.  Resveratrol improves health and survival of mice on a high-calorie diet , 2006, Nature.

[40]  M. Pape,et al.  Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome Published, JLR Papers in Press, April 21, 2004. DOI 10.1194/jlr.M400018-JLR200 , 2004, Journal of Lipid Research.

[41]  R. Moreno-Sánchez,et al.  Multisite control of the Crabtree effect in ascites hepatoma cells. , 2001, European journal of biochemistry.

[42]  R. DePinho,et al.  Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. , 2007, Cell metabolism.

[43]  Yvonne Will,et al.  Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[44]  J. Bar-Tana,et al.  Hypolipidemic, Antiobesity, and Hypoglycemic-Hypoinsulinemic Effects of β,β′-Methyl-Substituted Hexadecanedioic Acid in Sand Rats , 1988, Diabetes.

[45]  J. Bar-Tana,et al.  Inhibition of lipid synthesis by beta beta'-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in the rat in vivo. , 1985, The Journal of biological chemistry.

[46]  H. Yamashita,et al.  Mechanism for Fatty Acid “Sparing” Effect on Glucose-induced Transcription , 2002, The Journal of Biological Chemistry.

[47]  J. Lowenstein.  Effect of (-)-hydroxycitrate on fatty acid synthesis by rat liver in vivo. , 1971, The Journal of biological chemistry.

[48]  J. Pill,et al.  BM 17.0744: a structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity. , 1999, Metabolism: clinical and experimental.

[49]  B. Kalderon,et al.  Suppression of hepatocyte nuclear factor-4α by acyl-CoA thioesters of hypolipidemic peroxisome proliferators , 2001 .

[50]  J. Dietschy,et al.  Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. , 1993, Journal of lipid research.

[51]  Miao Zhang,et al.  Activation of Protein Phosphatase 2A by Palmitate Inhibits AMP-activated Protein Kinase* , 2007, Journal of Biological Chemistry.

[52]  K. Tronstad,et al.  Metabolic effects of thia fatty acids , 2002, Current opinion in lipidology.

[53]  R. Zeng,et al.  Abrogation of hepatic ATP‐citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor‐deficient mice , 2009, Hepatology.

[54]  R. Ceddia,et al.  Regulation of AMP-activated protein kinase and acetyl-CoA carboxylase phosphorylation by palmitate in skeletal muscle cells Published, JLR Papers in Press, November, 22, 2005. , 2006, Journal of Lipid Research.

[55]  S. Skrede,et al.  Thia fatty acids, metabolism and metabolic effects. , 1997, Biochimica et biophysica acta.

[56]  T. Rea,et al.  A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. , 1998, Journal of lipid research.

[57]  J. Dietschy,et al.  Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster. , 1988, The Journal of clinical investigation.

[58]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[59]  J. Bar-Tana,et al.  Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs. , 1995, The Journal of Biological Chemistry.

[60]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[61]  Bruce M. Spiegelman,et al.  Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction , 2003, Nature.

[62]  Guillaume Adelmant,et al.  Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1 , 2001, Nature.

[63]  J. Bar-Tana,et al.  Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids. , 1989, Journal of medicinal chemistry.

[64]  P. Aukrust,et al.  Anti-inflammatory and hypolipidemic effects of the modified fatty acid tetradecylthioacetic acid in psoriasis – a pilot study , 2011, Scandinavian journal of clinical and laboratory investigation.

[65]  M. Owen,et al.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.

[66]  Mengle Shao,et al.  Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice[S] , 2010, Journal of Lipid Research.

[67]  Dorothy D. Sears,et al.  Functional Heterogeneity of CD11c-positive Adipose Tissue Macrophages in Diet-induced Obese Mice* , 2010, The Journal of Biological Chemistry.

[68]  R. Schwendener,et al.  Inflammation Is Necessary for Long-Term but Not Short-Term High-Fat Diet–Induced Insulin Resistance , 2011, Diabetes.

[69]  E. Nishio,et al.  Effects of dietary cholesterol and fatty acids on plasma cholesterol level and hepatic lipoprotein metabolism. , 1990, Journal of lipid research.

[70]  J. Bar-Tana,et al.  Inhibition of Atherosclerosis and Myocardial Lesions in the JCR:LA-cp Rat by β,β′-Tetramethylhexadecanedioic Acid (MEDICA 16) , 1995 .

[71]  R. Hegele,et al.  Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. , 2011, The Canadian journal of cardiology.

[72]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[73]  C. Southan,et al.  Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age. , 1990, The Journal of biological chemistry.

[74]  J. Manson,et al.  Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. , 2012, Archives of internal medicine.

[75]  Xiao Wang,et al.  Palmitate activates AMP-activated protein kinase and regulates insulin secretion from beta cells. , 2007, Biochemical and biophysical research communications.

[76]  P. Thompson,et al.  Statin-associated myopathy. , 2003, JAMA.

[77]  R. Harris,et al.  Mechanism responsible for 5-(tetradecyloxy)-2-furoic acid inhibition of hepatic lipogenesis. , 1979, The Journal of biological chemistry.

[78]  J. Bar-Tana,et al.  Inhibition of lipid synthesis by beta beta'-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in cultured rat hepatocytes. , 1985, The Journal of biological chemistry.

[79]  R. Geyer,et al.  Quantitative extraction of microgram amounts of lipid from cultured human cells. , 1977, Analytical biochemistry.

[80]  J. Bar-Tana,et al.  Inhibition of rat liver acetyl-CoA carboxylase by β,β′-tetramethyl-substituted hexadecanedioic acid (MEDICA 16) , 1990 .

[81]  B. Kemp,et al.  Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. , 2011, The Journal of clinical investigation.

[82]  K. Watson,et al.  Effective strategies for long-term statin use. , 2003, The American journal of cardiology.

[83]  C. Ballantyne,et al.  ETC-1002 LOWERS LDL-C AND BENEFICIALLY MODULATES OTHER CARDIO-METABOLIC RISK FACTORS IN HYPERCHOLESTEROLEMIC SUBJECTS WITH EITHER NORMAL OR ELEVATED TRIGLYCERIDES , 2012 .

[84]  H. Lodish,et al.  Activation of AMP‐activated protein kinase signaling pathway by adiponectin and insulin in mouse adipocytes: requirement of acyl‐CoA synthetases FATP1 and Acsl1 and association with an elevation in AMP/ATP ratio , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[85]  J. Bremer.  The biochemistry of hypo- and hyperlipidemic fatty acid derivatives: metabolism and metabolic effects. , 2001, Progress in lipid research.

[86]  H. Brewer,et al.  Modulation of the enzymic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by multiple kinase systems involving reversible phosphorylation: a review. , 1987, Metabolism: clinical and experimental.

[87]  R. Srivastava,et al.  Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster , 2010, Molecular and Cellular Biochemistry.

[88]  R. Parker,et al.  5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids. , 1977, Journal of medicinal chemistry.

[89]  Yu Hong,et al.  AMP-activated Protein Kinase Regulates HNF4α Transcriptional Activity by Inhibiting Dimer Formation and Decreasing Protein Stability* , 2003, Journal of Biological Chemistry.

[90]  C. Carlson,et al.  Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. , 1973, The Journal of biological chemistry.

[91]  D. Hardie,et al.  Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. , 1988, European journal of biochemistry.

[92]  L. Havekes,et al.  The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. , 1990, The Biochemical journal.

[93]  D. B. Zilversmit,et al.  Effects of hyperlipidemias in hamsters on lipid transfer protein activity and unidirectional cholesteryl ester transfer in plasma. , 1991, Biochimica et biophysica acta.

[94]  R. Ulrich,et al.  Isolation and culture of hepatocytes from the cynomolgus monkey (Macaca fascicularis) , 1990, In Vitro Cellular &Developmental Biology.

[95]  Justin R. Cross,et al.  ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation , 2009, Science.

[96]  Jennifer G. Robinson,et al.  Management of the Patient with Statin Intolerance , 2010, Current atherosclerosis reports.

[97]  B. Kalderon,et al.  AMPK activation by long chain fatty acyl analogs. , 2008, Biochemical pharmacology.

[98]  J. Lowenstein,et al.  3- -Hydroxysterol synthesis by the liver. , 1972, Archives of biochemistry and biophysics.

[99]  David Carling,et al.  Covalent activation of heart AMP-activated protein kinase in response to physiological concentrations of long-chain fatty acids. , 2004, European journal of biochemistry.

[100]  D. Rudy,et al.  Intracellular mechanisms regulating apoB-containing lipoprotein assembly and secretion in primary hamster hepatocytes. , 2000, Journal of lipid research.

[101]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[102]  M. Febbraio,et al.  Fatty acids stimulate AMP‐activated protein kinase and enhance fatty acid oxidation in L6 myotubes , 2006, The Journal of physiology.

[103]  K. Decker,et al.  Inhibition of cholesterol synthesis by (−)‐hydroxycitrate in perfused rat liver. Evidence for an extramitochondrial mevalonate synthesis from acetyl coenzyme A , 1972, FEBS letters.

[104]  C. Chu,et al.  A novel direct homogeneous assay for ATP citrate lyase[S] , 2009, Journal of Lipid Research.

[105]  A. Cahan,et al.  Suppression of FoxO1 Activity by Long-Chain Fatty Acyl Analogs , 2011, Diabetes.